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T issue remodelling, the acquisition of new tissue architecture resulting from the combined action of cells and their extracellular matrix (ECM), is a feature of normal development and growth, as well as pathological situations and tissue repair. In most tissues, the amount of ECM equals or exceeds the cellular component and most of the ECM is synthesized by mesenchymal cells (fibroblasts, myofibroblasts and smooth muscle cells). Epithelial and endothelial cells also contribute by synthesizing specialised ECM structures such as basement membranes, which have both functional and protective roles. Exactly how cells orchestrate the organisation of the ECM remains largely unclear but extracellular and cell surface proteases have clearly been identified as key players due to their ability to synchronize matrix synthesis and degradation with the activation and deactivation of growth factors and other cytokines. While normal tissue homeostasis depends on a controlled balance between synthesis and degradation, loss of homeostasis in diseases of the skin, cornea or internal organs can lead either to excessive production (e.g. fibrosis, hypertrophic scarring) or excessive destruction (e.g. arthritis, emphysema, chronic ulcers) of ECM. Until recently, remodelling was regarded almost exclusively from the destructive point of view with little attention being paid to synthesis. This is explained by the intensive research for new anti-tumoral agents and by the great expectations raised by inhibitors of matrix metalloproteinases (MMPs). Even now, the remodelling literature only rarely mentions proteases involved in ECM synthesis and one major aspect of this review is to recognize the importance of proteases such as tolloids and ADAMTSs in the maturation of matrix components. In recent years, using knock-out mice and novel tools such as activity-based probes and high-throughput proteomics, researchers have achieved real progress towards understanding the "protease web" [1] which links proteases to other proteases, to their substrates, their inhibitors and their various binding partners. However, it remains a challenge to link substrates with observations at the cellular or tissue level, and in vivo extrapolation of processing events observed in vitro is made difficult by the intrinsic complexity of the extracellular matrix. Substrates can be masked by interaction partners, they can adopt different conformations, or be physically entrapped or otherwise inaccessible to proteases, due to spatial or temporal separation. In contrast to most other post-translational modifications, proteolytic events are irreversible and therefore fine tuning of protease activity is required to avoid tissue destruction. For all types of extracellular proteases, inhibitors have been described, either broad-spectrum, such as α2-macroglobulin [2] , or more specific to a protease family, such as TIMPs for MMPs. More recently, mechanisms for enhancement of proteolytic activity have also been described and, interestingly, these usually provide a means to direct protease activity to particular substrates. Other regulatory mechanisms following secretion include propeptide removal, feedback loops involving processed substrates and control of extracellular localisation. In this review, we give examples of these various aspects and present an overview of the properties and functions of the extracellular and cell surface proteases (mainly serine proteases and metalloproteases) involved in wound healing. This well known case of tissue remodelling illustrates all the different functions with which extracellular and cell surface proteases are known to be involved: matrix protein synthesis and degradation; release of cryptic bioactive fragments; regulation of growth factors and other cytokines; and the control of cell adhesion, migration, apoptosis and signalling.
Extracellular and cell surface proteases: old and new players
The functional importance of proteases is demonstrated by the fact that more than 2% of the genes present in the human genome consist of proteases and protease inhibitors. These proteases are classified according to their catalytic mechanism and to the particular amino acid/ cofactor responsible for water activation or nucleophilic attack during hydrolysis. Among the 569 human proteases [3] , the most abundant are serine and threonine proteases (176 proteins) and metalloproteases (194 proteins) but cysteine and aspartate proteases also play major roles. In each class, subfamilies can be identified according to their localization: intracellular, extracellular or associated with the cell surface. In this review, the focus will be on the extracellular and cell surface associated proteases involved in wound healing. These cluster into three main groups: serine proteases (mainly proteases from the plasminogen/plasmin system), cysteine proteases and lastly metalloproteases from the metzincin superfamily, which are by far the most abundant (more than 80 members if MMPs, ADAM(TS)s, tolloids, meprins and pappalysins are included). The key importance of plasmin and metzincins in skin repair was clearly shown by Lund and co-workers [4] who demonstrated that healing was significantly delayed in wounded mice either deficient in plasminogen or treated with a broad-spectrum metalloprotease inhibitor (galardin) but was completely blocked when both effects were combined. Each protease family could be the subject of an article in its own right; here we present the main features of these enzymes and refer the reader to the numerous reviews now available for more detailed information.
Serine and cysteine proteases
In contrast to the metalloproteases that will be described below, serine proteases do not form a homogeneous family with large structural and regulatory differences. Most of the proteases found in the blood circulation (mainly kallikreins [5, 6] and proteases of the coagulation and complement cascades) are serine proteases which can potentially impact remodelling processes such as angiogenesis and wound healing. Also important are members of the relatively new family of type II transmembrane serine proteases (TTSPs; [7] ) among which the matriptases play an important role in wound healing through activation of pro-hepatocyte growth factor/scatter factor [8] . Neutrophil elastase seems to play a major role in the onset of inflammatory responses, especially in the lung where, in the absence of tight regulation, changes in neutrophil elastase activity can lead to excessive matrix degradation (emphysema) or excessive matrix production (lung fibrosis) [9] . Finally, we should mention two serine proteases related to neutrophil elastase, also produced by inflammatory cells, proteinase 3 and cathepsin G [10] , as well as other members of the cathepsin family which are better known but belong to the class of the cysteine proteases (cathepsins B, K, L, S and V). Cysteine cathepsins can degrade fibrillar collagens, elastin and some other extracellular components in acidic pericellular environments [11, 12] . These enzymes have been mainly associated with cardiovascular diseases, cancer progression and bone remodelling; their roles in wound healing remain relatively elusive. More broadly relevant in the wound healing context are proteases from the plasmin system, which are not only responsible for fibrin clot lysis [13] but can also participate in TGF-β activation [14, 15] , cleave components of the extracellular matrix (laminin 332 [16] , thrombospondin-1, fibronectin [17] ) or activate other proteases (especially MMPs) which will in turn degrade ECM. In addition, as mentioned above, the crucial role of plasmin in tissue repair has been demonstrated in mice deficient in plasminogen [4, 18] . Figure 1 illustrates the complex regulation of plasminogen conversion into the active plasmin form [13] . Plasmin activation can be seen as a paradigm for protease regulation with both enhancing and inhibiting mechanisms both contributing to the fine tuning of protease activity. The conversion of plasminogen to plasmin is mainly carried out by two other serine proteases: tPA (tissue-type plasminogen activator) and uPA (urokinase-type plasminogen activator) with the latter being the most important for tissue remodelling and the former for fibrin clot dissolution. Several modulators of plasmin, tPA and uPA have been described that, in some cases, can act in a substratespecific manner. Such substrate-specific regulation is frequently encountered with proteases, but rarely with other types of enzymes. For example, fibrin, the major plasmin substrate, binds both tPA and plasminogen, thereby increasing tPA catalytic efficiency and enhancing fibrinolysis [13] . In addition, uPA can be recruited and activated more efficiently at the cell surface via a specific receptor uPAR (uPA receptor). uPAR can then associate with a variety of cell receptors, including integrins, and modulate cell adhesion [19, 20] . Through a positive feedback loop, plasmin cleaves tPA and uPA and the resulting two-chain plasminogen activators are more active than the single chain proteases. Finally, two inhibitors of the plasminogen activators (PAI-1 and PAI-2) and inhibitors of plasmin (such as α2-plasmin inhibitor) further regulate plasmin activation. This results in a complex pathway of plasmin maturation, as described in figure 1 , accounting for the destructive potential associated with this protease.
Metalloproteases
Most extracellular metalloproteases belong to the metzincin superfamily which is defined by a conserved zinc-binding motif (HEXXHXXG/NXXH/D) and a methionine-containing turn near the active site [21, 22] . This family is further divided into 6 different subgroups: sins. With the exception of the last two groups, all these families are involved in remodelling processes.
Matrix metalloproteases (MMPs)
MMPs are, without contest, the most well-known of all remodelling enzymes and have been extensively studied in several contexts (cancer, cardiovascular diseases, wound healing, bone remodelling, pregnancy…) for the past 30 years. MMP activity is inherently involved in remodelling since, in normal situations, these enzymes are expressed at virtually undetectable levels with a few exceptions such as MMP-7 which is constitutively expressed in epithelial cells [23, 24] . Their expression becomes elevated when there is a challenge to the system, such as wound healing and disease [25] . The initial classification of the 23 human MMPs according to their substrate specificity and functional characteristics (collagenases, gelatinases, broadspecificity stromelysins, membrane-bound MMPs…) has now given way to a simple numbering scheme. While all MMPs have in common a signal peptide, a propeptide and a catalytic domain, they differ by the possible insertion of fibronectin-type II repeats in the catalytic domain (MMPs-2 and -9), the presence of a haemopexin domain involved in substrate recognition (in all MMPs except MMPs-7 and -26), an additional transmembrane domain followed by a cytoplasmic tail (MMPs-14, -15, -16 and 24) or a GPI anchor (MMPs-17 and -25) [26] . The propeptide is cleaved off either in the Golgi apparatus by proteases from the furin-like proprotein convertase family or pericellularly by plasmin, other MMPs or by autoproteolysis. As a family, MMPs can cleave all extracellular matrix components (collagens, elastin, proteoglycans and other structural glycoproteins). They are also involved in growth factor activation (e.g. TGF-β and VEGF: see below) and can modify cell-matrix and cell-cell interactions in several ways (including matrix degradation, shedding of syndecans and cadherins, and binding of integrins and CD44) [27, 28] . After propeptide removal, MMP activity is regulated by potent inhibitors of the TIMP family (Tissue Inhibitors of MMPs 1-4) which have also been implicated in a range of biological processes, grossly overlapping MMP functions but with opposite effects: tumour metastasis, angiogenesis, wound healing, cell differentiation and survival, inflammatory responses, etc. TIMPs bind to the catalytic zinc ion of MMPs, thus blocking access to the catalytic pocket. All MMPs can be inhibited by all TIMPs but to variable extents [29] . The main structural and regulatory features of this family are also summarized in figure 1.
ADAMs and ADAMTSs
The adamalysin family is the largest family of metalloproteases in terms of numbers with 40 human ADAMs (A Disintegrin And Metalloprotease) and 19 ADAMTSs (ADAMs with thrombospondin (TS) motifs). Among the ADAMs, only 13 are predicted to be catalytically active, and many have lost the ability to bind zinc, pointing to additional, non-enzymatic roles, for example in cell adhesion. ADAMs and ADAMTSs share some structural similarities (a catalytic domain followed by a disintegrin domain and a cysteine-rich domain: figure 1 ) but major differences in their cellular localizations and substrate specificities have led to divergent biological functions.
With a few exceptions, ADAM proteins remain attached to the plasma membrane and the catalytic activity of the ADAMs that are predicted to be active (8-10, 12, 15, 17, 19-21, 28, 30, 33 ) is devoted to the shedding of the ectodomain of several transmembrane proteins. They release diffusible factors, such as heparin-binding EGF (HB-EGF) or TNF-α, from their membrane-anchored precursors. They also cleave adhesion molecules (e.g. cadherins and CD44) to disrupt adhesive contacts while shedding of signalling receptors (e.g. the Notch receptor) leads to further intra-membrane proteolysis and release of an intracellular domain which becomes a signal transducer (see below). In the latter case, binding of a substrate ligand, such as Delta in the case of the Notch receptor, is often required to trigger proteolysis by ADAMs and permits very strict regulation of the downstream signalling pathway. The ADAMs that are proteolytically inactive can nevertheless play important roles, especially in cell adhesion, via their disintegrin and cysteine-rich domains. The disintegrin domains of several ADAMs, for example, have been shown to bind to receptors of the integrin family and thereby block their function. Furthermore, the cysteine-rich domain can interact with ECM proteins such as fibronectin and heparan-sulphate proteoglycans of the syndecan family. In contrast to the ADAMs, ADAMTSs are all secreted proteases and are found either in soluble form or bound to the ECM. Their key feature is a variable number of type 1 thrombospondin repeats (figure 1). They are all supposedly active but six of the ADAMTS are orphans with no known substrates. Other ADAMTSs tend to be much more specific than the metalloproteases described so far and their main remodelling functions can be classified into 3 overlapping groups [30] : (i) the anti-angiogenic ADAMTSs (-1 and -8), this function being directly mediated by their TS motifs or through the release of antiangiogenic factors such as thrombospondin fragments [31] (ii) the aggrecanases (-1, -4, -5, -8, -9 and -15) which cleave aggrecan and are the main players during joint degeneration and (iii) the procollagen N-proteinases (-2, -3 and -14) which are involved in processing of fibrillar collagen precursors. For both ADAMs and ADAMTSs, propeptide removal is carried out by proteases of the proprotein convertase family in the Golgi apparatus. The only protein inhibitors that have been described so far for ADAMs are the TIMPs but in contrast to the MMPs, not all members of the family are inhibited by the four TIMPs and the physiological consequences of this inhibition are not very well documented. TIMP-3, which is unique among the TIMPs for its ability to interact strongly with ECM, is also a potent inhibitor of the catalytic domain of ADAM-10 and -17 [32, 33] . In the ADAMTS family, full-length ADAMTS-4 and -5 have also been shown to be inhibited by TIMP-3 [34] . Interestingly, TIMP-3 is not a good inhibitor of ADAMTS-2 but this particular enzyme has been shown to be inhibited by papilin [35] , a protein found in the basement membrane which contains the C-terminal, non catalytic domains of ADAMTSs. Finally, ADAMTS-1-dependent cleavage of aggrecan seems to be enhanced by fibulin-1 through simultaneous binding of both protease and substrate [36] . For a more comprehensive overview of the members and roles of both families, we recommend the recent reviews by Tousseyn et al. and Edwards et al. on ADAMs [37, 38] and Porter et al. on ADAMTSs [30] .
Tolloids
Tolloid proteinases are also known as procollagen Cproteinases (PCPs) or by the names of the four members of the family (BMP-1, mTLD, mTLL-1 and mTLL-2). BMP-1 (bone morphogenetic protein-1) and mTLD (mammalian tolloid) are splice variants of a single gene whereas mTLL-1 and 2 (mammalian tolloid like-1 and -2) are the products of two separate genes. Members of this family were originally linked exclusively to collagen maturation as one of their major roles is to cleave the C-terminal propeptides of procollagens I, II and III, thereby triggering fibril formation. However, a variety of new substrates have been discovered in the past decade [39] and tolloids now appear as key players in various biological functions ranging from embryogenesis and morphogenesis to ECM biosynthesis. For example, they control dorso-ventral patterning in the embryo through the cleavage of chordin, a growth factor antagonist, as well as morphogenetic events such as muscle growth and neural differentiation through the activation of GDF-8 and -11. It was also recently established that tolloids can cleave latent TGF-β binding proteins (LTBPs) thereby releasing latent TGF-β from the matrix and triggering TGF-β activation [40] (figure 2). In addition, they process several partners involved in collagen fibrillogenesis and participate in basement membrane assembly through the processing of laminin 332 [41] and procollagen VII [42] . Finally, tolloid proteinases probably also play a role in angiogenesis with the recent discovery of substrates such as endorepellin [43] and prolactin [44] . A unified view suggesting that this family of proteases could act to synchronize signalling pathways with ECM biosynthesis, a crucial requirement during morphogenesis and tissue remodelling, is now emerging. From a structural point of view, tolloid proteinases comprise a catalytic domain of the astacin type and a variable number of CUB and EGF domains (figure 1). Their propeptides are also removed by furin-like proteases, as for some MMPs and almost all ADAM(TS)s. Tolloids are soluble proteins which are regulated substrate-specific enhancers. In addition, in Xenopus, it has been shown that the Sizzled protein binds strongly to tolloids and inhibits cleavage of chordin [45] , suggesting that homologous secreted frizzled-related proteins might play similar roles in mammals (though not supported by recent data, [46] ). Tolloids are also regulated by enhancer proteins which are substrate-specific in that they specifically activate the cleavage of only one type of substrate, for example procollagen C-proteinase enhancers (PCPEs) in the case of the fibrillar procollagen substrates [47] or twisted gastrulation and olfactomedin in the case of chordin [48, 49] . Roles of tolloid proteinases in wound healing. Tolloid proteinases act on several substrates, either alone or in combination with other types of protease (cleavage sites indicated by scissors), in order to regulate collagen and elastin fibrillogenesis, angiogenesis, basement membrane assembly, cell migration and growth factor activation. ECM = extracellular matrix; LTBP = latent transforming growth factor binding protein; LAP = latency associated peptide.
Other metalloproteases
Two other families of metzincins are also slowly making their way into the remodelling field: pappalysins and meprins. The best studied member of the pappalysin family is PAPP-A (Pregnancy-Associated Plasma Protein-A) which cleaves IGF binding proteins 2, 4 and 5, thereby releasing sequestered IGF-I and II with effects on cell proliferation, migration and differentiation. Elevated levels of this protease are found in the circulation of pregnant women and of patients with acute coronary syndromes. PAPP-A also seems to play a role during wound healing with an increased expression in the dermis and epidermis [50] . The proteolytic activity of PAPP-A is inhibited, in an unusual and probably irreversible manner, by the proform of eosinophil major basic protein (pro-MBP), which forms a covalent 2:2 proteinase-inhibitor complex based on disulfide bonds [51] . Interestingly also, upon IGF binding, cleavage of IGFBP-2 and 4 is enhanced many fold while cleavage of IGFBP-5 is slightly inhibited [52] . Meprins, like tolloid enzymes, are proteases of the astacin family [21] , which, unlike tolloid proteases, are synthesised as transmembrane proteins. They are expressed as two independent subunits (α and β) which can assemble into hetero-or homo-dimers, or higher oligomers in the case of meprin α, which can be released from the plasma membrane by proteolytic shedding. Expression of meprins has been reported mainly in the kidney, intestine and skin but could increase during inflammatory conditions, cancer progression and wound healing. In recent years, meprins have been shown to cleave several ECM proteins (collagen IV, laminin 111, nidogen-1, fibronectin), enzymes such as lysyl oxidases and adhesion proteins such as cadherins but the discovery of physiologically relevant substrates is still a matter of intense research. The only endogenous inhibitor described so far for meprins is mannan-binding lectin [53] but the primary regulatory mechanism of meprins after propeptide removal seems to be targeting to specific locations (e.g. apical membrane of polarized cells).
Extracellular and cell surface proteases in wound healing
The most common case of tissue remodelling, tissue repair, occurs after various types of traumatic lesions (wounds, burns, surgery…). Tissue repair is usually described as being divided into three phases which partially overlap, while the entire process can take several months. During the first phase, haemostasis and inflammation, a fibrin-rich provisional matrix is formed as a result of thrombin and platelet activation. Fragments of coagulation factors, activated complement components, growth factors and chemokines released by damaged cells and activated platelets then recruit inflammatory cells to the site of injury [54, 55] . Platelets, for example, are major sources of TGF-β and PDGF. First to arrive are the neutrophils, which cleanse the wound area by phagocytosis and the release of antimicrobial substances (reactive oxygen species, cationic peptides, eicosanoids) and proteases (neutrophil elastase, cathepsin G, proteinase 3, uPA, MMPs-8 and -9) [56] . Migration of neutrophils from the blood capillaries into the wound site involves interactions with endothelial cell adhesion molecules such as selectins and ICAMs. Subseqently, monocytes also infiltrate the wound site, in response to growth factors (TGF-β, PDGF) and chemokines (e.g. monocyte chemoattractant proteins or MCPs) where they become activated and differentiate into mature tissue macrophages. While both neutrophils and macrophages produce pro-inflammatory mediators (TNF-α, interleukins-1 and -6), macrophages also synthesize several growth factors (TGF-β, TGF-α, bFGF, PDGF, VEGF) to stimulate the repair response.
In the second phase, re-epithelialisation and granulation tissue formation, which commences soon after injury, keratinocytes use the provisional fibrin-rich matrix to migrate and cover the wound area. This requires the coordinated action of several growth factors and cytokines, together with multiple proteases and adhesion proteins involved in cell-cell and cell-matrix interactions. Important growth factors involved in re-epithelialisation include members of the EGF family (EGF, TGF-α, HB-EGF) and FGFs, which promote keratinocyte proliferation, and TGF-β, which negatively regulates this process [57] . Next, about 4 days after injury, fibroblasts are also attracted to the wound area to initiate the formation of granulation tissue, which includes a new extracellular matrix rich in collagen III, fibronectin and proteoglycans.
Cross-talk between keratinocytes and fibroblasts plays an important role, notably in the production of a new basement membrane, as well as in the control of cell proliferation. Fibroblast proliferation is stimulated by different growth factors (including PDGF, TGF-β, CTGF, IGFs) some of which also promote the important process of wound contraction by stimulating fibroblast differentiation into myofibroblasts. In addition to the acquisition of a contractile phenotype, these myofibroblasts also demonstrate an enhanced ability to synthesize extracellular matrix. Finally, formation of granulation tissue also requires new blood vessel formation, angiogenesis, under the control of different growth factors (notably VEGF) as well as anti-angiogenic factors released by proteolysis (see below). In the final phase of tissue repair, tissue remodelling, the granulation tissue is progressively replaced by a more mature scar tissue, where collagen I is the major component. Remodelling is a lengthy process, which requires both synthesis and degradation of ECM in order to recreate as closely as possible, but never completely, the properties of the original tissue. At the end of wound repair, myofibroblasts usually undergo apoptosis and are replaced by normal fibroblasts. However, in certain pathologies, excessive inflammation can lead to persistence of myofibroblasts and excessive ECM synthesis, leading to hypertrophic scarring, or complete failure to heal, as in chronic wounds (ulcers). Proteases play numerous roles during the process of wound healing (table 1) . They are at work during: haemostasis; regulation of the activities of growth factors, chemokines and other cytokines; cell migration, signalling and survival; angiogenesis; and synthesis and remodelling of the extracellular matrix.
Haemostasis and inflammation
Upon injury, damage to the blood vessel wall exposes sub-endothelial proteins, notably collagens, to which platelets bind via specific glycoprotein receptors, resulting in platelet activation and subsequent aggregation. Formation of the platelet plug is stabilised by interaction with von Willebrand factor, which itself is a substrate for ADAMTS-13 [30] . In addition, negative regulation of aggregation occurs by proteolytic release from the cell surface, or shedding, of platelet glycoprotein receptors by ADAM-17/TACE [58] . The platelet plug is further stabilised by the formation of a fibrin-rich network resulting from thrombin activation, via the coagulation cascade, and subsequent maturation of fibrinogen. Circulating leukocytes then infiltrate into the wound area first by attachment to the endothelial cells of the blood vessel wall followed by extravasation into the surrounding tissue. This involves tethering to specific cell adhesion molecules expressed on the endothelial cells, notably Eselectin, ICAM-1 and VCAM-1, whose expression is induced by inflammatory cytokines [59] . Subsequent extravasation through the blood vessel wall requires additional cell adhesion molecules such as PECAM-1 [60] . These processes are under the control of multiple proteases (notably ADAMs-10 and -17) through shedding of ICAM-1, VCAM-1 and PECAM-1 from endothelial cells, as well as by shedding of L-selectin from neutrophils. Finally, neutrophil infiltration into the wound site is facilitated by secretion of the neutrophil collagenase MMP-8, probably through collagen degradation but also through proteolytic modification of chemotactic molecules [61, 62] . Migration of inflammatory cells into the wound site is actually controlled by several chemokines, many of which are regulated by the action of proteases [63, 64] . Protease activity can lead to increased or decreased activity, either directly, by proteolytic cleavage of the chemokine, or indirectly, by cleavage of interaction partners or receptors. Particularly well studied are the monocyte chemoattractant proteins (MCPs) which serve to attract monocytes to the site of tissue injury. A number of MMPs have been found to cleave short N-terminal fragments from different MCPs leading to a loss of chemokine activity and the generation of receptor antagonists [65] . Since these MMPs are produced by stromal cells as a result of macrophage-derived inflammatory cytokines, such activity could serve to dampen the inflammatory response. Alternatively, other chemokines can be directly activated by proteolytic activity, either by the processing of inactive precursors (such as IL-8/CXCL8 activation by serine proteases, cathepsin L or MMP-9) or by shedding of membrane-bound precursors (such as CX3CL1/fractalkine by MMP-2 [66] , ADAMs-10 and -17 [67] ). Furthermore, since IL-8 binds to the heparan sulphate chains of cell surface syndecan-1, MMP-7 shedding of the IL-8/syndecan-1 complex can help establish local chemokine gradients at the wound site [63] . Finally, ADAM-17/TACE also plays a key role in the regulation of proinflammatory cytokines, both by the shedding of TNF-α from the cell surface, as well as by the shedding of both TNF-α and IL-6 receptors [38] . Similarly, MMPs-7 and -12 may also release TNF-α from macrophages, while MMPs-2,-3 and -9 are involved in the activation and inactivation of IL-1β [63] .
Re-epithelialisation, angiogenesis and granulation tissue formation
Re-epithelialisation, angiogenesis and granulation tissue formation are also governed by the orchestrated action of numerous growth factors as well as multiple proteases involved in growth factor release from the matrix or from the cell surface, control of cell signalling and modulation of cell-matrix and cell-cell interactions. Different growth factors are involved in each step, including TGF-α, HB-EGF and KGF in epithelial cell (keratinocyte) proliferation and migration; bFGF, VEGF and TGF-β in angiogenesis; and TGF-β, PDGF, CTGF and IGF in fibroblast proliferation and ECM production; while other growth factors, such as HGF/SF, have more general effects [8, 57] . Many of the examples described below show the importance of proteolytic processing at the cell surface, not only for transmembrane proteases (ADAMs, meprins, membrane type MMPs, matriptases) but also for other proteases that are anchored to the plasma membrane, either directly, through a GPI anchor (MMPs-17,-25), or indirectly, in association with cell surface receptors. Examples of the latter are binding of MMP-9 to the hyaluronan receptor CD44 [68] , MMP-2 to integrin α v β 3 , MMP-1 to integrin α 2 β 1 and MMP-7 to heparan sulphate proteoglycans [63] . Such interactions serve to localise the site of proteolysis, or protease activation, as well as to bring proteases and their substrates in closer proximity.
Release of growth factors sequestered in the extracellular matrix
One function of proteases is to mobilise growth factors, such as VEGF, FGF, PDGF, CTGF and TGF-β, by release from matrix-bound stores [27, 69, 70] . For example, angiogenic factors such as VEGF and bFGF associate with heparan sulphate proteoglycans found in the matrix and must be released to promote angiogenesis. MMP-9 is thought to be the main enzyme involved in the release of VEGF [71] but other mechanisms involving MMP-2 have been described [25, 72] . Interestingly, the released and matrix-bound forms of VEGF have different properties, the former inducing endothelial cell proliferation, the latter stimulating vascular sprouting and branching [73] . MMP-2 can also unmask VEGF by cleaving inhibitory partners such as pleiotrophin/HARP and CTGF [74] . Similarly, IGFs are antagonized by six different IGF binding proteins that can be cleaved by pappalysins, MMPs, cathepsins, kallikreins or other serine proteases [75] .
The activation of TGF-β has been extensively studied, and several mechanisms, both proteolytic and non-proteolytic, have been elucidated. TGF-β, (of which there are three variants β1, β2 and β3), is secreted as a latent dimeric complex consisting of the functional growth factor at the C-terminus and the latent prodomain (called LAP or latency-associated peptide) at the N-terminus. TGF-β is cleaved from its propeptide during secretion by furin-like proteases and remains bound to LAP in a non-covalent manner. LAP can also form disulphide bridges with latent TGF-β binding proteins LTBPs-1, -3 or -4 [76] to produce LLC (large latent complex). Because LTBPs have a strong affinity for several matrix components, especially fibrillin-1 [77, 78] , LLC is deposited within the extracellular matrix, to which it is covalently bound by transglutaminase cross-linking [79] . Release of the TGF-β/LAP complex from the ECM requires proteolysis of the LTBP and this processing was recently attributed to tolloids [40] (Fig.2) . Subsequently, active TGF-β can be released from the complex by another round of proteolysis, this time under the control of plasmin [14] or MMPs-2, -9 and -14, themselves possibly in association with integrins, to which LAP also binds [68, 79, 80] . Conformational changes leading to TGF-β activation in the absence of proteolytic activity have also been demonstrated, the first being mediated by thrombospondin-1 (TSP-1) which can bind to LAP associated with TGF-β [81] . This interaction appears to induce a conformational change in the prodomain which, while remaining bound to mature TGF-β, leads to a loss of latency and hence TGF-β activation [82] . More recently, it has been shown that mechanical forces exerted by myofibroblasts attached to an extracellular matrix substrate can directly lead to TGF-β activation, through an LTBP-dependent but nonproteolytic pathway [83] . With LAP bound to different types of integrins via its RGD motif, cell shape change or movement can distort the structure of the latent complex, thereby releasing active TGF-β [79] . Interestingly, this mechanism only works when cells remain bound to a relatively rigid substrate, in order to provide sufficient mechanical traction, thereby demonstrating the importance of the physical properties of the extracellular matrix in growth factor activation.
Release of membrane-bound growth factors and control of cell signalling
Growth factors can also be activated by proteolytic release, or shedding, from the cell surface. For example, growth factors of the EGF family, notably TGF-α and heparin binding (HB)-EGF have been shown to play important roles in wound healing, particularly in reepithelialisation [57] . All EGF receptor ligands are synthesized as membrane-anchored forms, which are activated by ectodomain shedding from the cell surface. One of the best described examples is the shedding of HB-EGF by ADAMs-9, -10, -12 or -17 [84] . HB-EGF is expressed on the cell surface of keratinocytes and in the event of injury, expression of ADAMs leads to shedding of the growth factor and transient stimulation of the EGF receptor which is required for keratinocyte migration. In addition, shedding of the extracellular domain of HB-EGF also results in the release of a C-terminal cytosolic fragment that can be translocated to the nucleus where it associates with transcription factors involved in cell cycle control [85] . In addition to growth factor activation, shedding also plays a role in cell signalling. One of the best studied examples is the Notch signalling pathway which is involved in a large panel of developmental events and in several cancers [86] and was recently shown to be directly involved in wound healing [87] . Thus, when Notch signalling is blocked, delayed healing is observed, due to changes in endothelial cell, keratinocyte and fibroblast migration. Both the Notch receptor and its ligands (members of the Delta and Jagged families) are transmembrane proteins with large extracellular domains and as a consequence, interaction between receptor and ligands is restricted to neighbouring cells. When a ligand is bound to the Notch receptor, two sequential proteolytic events are induced: the first cleavage is performed by ADAM-10 or -17 resulting in the release of the Notch extracellular domain, while the second cleavage occurs inside the membrane, by regulated intracellular proteolysis or RIPping, and is due to the γ-secretase complex [88] . The second cleavage promotes the translocation of the Notch intracellular domain into the nucleus with subsequent induction of transcriptional events. Another example of the importance of proteases in cell signalling has been described for the family of protease activated receptors (PARs). These are transmembrane Gprotein coupled receptors in which cleavage of part of the extracellular domain (usually by serine proteases) exposes a tethered ligand (part of the polypeptide chain) which then interacts with the rest of the molecule, thereby triggering intracellular signalling in an irreversible manner. Activation of PARs by thrombin can have a direct effect on the expression of profibrotic mediators such as PDGF and CTGF [89] , as well as TGF-β [90] and has been shown to be involved in tissue fibrosis.
Modulation of cell-matrix and cell-cell interactions
Both re-epithelialisation and angiogenesis involve several proteolytically regulated steps, including cell migration through the provisional matrix, and disruption/reestablishment of both cell-cell and cell-matrix contacts. For example, epithelial migration through the fibrin-rich matrix is in part due to activation of serum-derived plasmin by up-regulation of uPA and its receptor uPAR. Plasminogen-deficient mice show severely impaired reepithelialization in a skin wound model [91] . Similarly, laminin 332 (previously known as laminin 5) which connects basement membranes to integrins and syndecans on the epithelial cell surface can be cleaved by several proteases, including serine proteases, MMPs and tolloid proteases. These proteolytic events generally result in increased or decreased migration of epithelial cells, depending on which chain is processed and at which site [92, 93] . With regard to cell-cell interactions, those mediated by cadherins (E-cadherin in the case of keratinocytes or VEcadherin the case of endothelial cells) are also subject to protease regulated shedding. Several proteases are potentially involved, including MMPs-3,-7,-9,-12 and-14 [94, 95] , ADAM-10 [96] , neutrophil elastase [97] and meprin-β [98] . Shedding of cadherins can also result in translocation of membrane bound β-catenin to the cell nucleus, thereby leading to changes in cell proliferation [99] .
Another effect of ECM proteolysis is to expose cryptic sites or fragments (matricryptins) that change cell-matrix interactions [100, 101] . For example, PDGF-stimulated vascular smooth muscle cells migrate more rapidly on collagen I fragments generated by collagenase activity than on intact collagen [102] . This is due to changes in adhesion and migration mediated by a switch in integrin recognition from α 2 β 1 to α v β 3 . Similarly, MMP cleavage of basement membrane collagen IV exposes a cryptic site associated with increased angiogenesis coupled with decreased binding to integrin α 1 β 1 and increased binding to αvβ3 [103] . Further examples are the release of antiangiogenic fragments from pro-angiogenic molecules or even from proteases themselves, including: (i) angiostatin from plasmin [104] , (ii) anti-angiogenic fragments from basement membrane components, including endostatin from collagen XVIII, tumstatin, canstatin and arresten from collagen IV and endorepellin from perlecan [43, 101] , and (iii) anti-angiogenic fragments from prolactin and growth hormone [44] ( figure 2) . Finally, in addition to their effects on cell proliferation, signalling, adhesion and migration, extracellular proteases are also known to influence programmed cell death, apoptosis [105] . Proteolytic disruption of cell-matrix interactions can lead to apoptosis by the process of anoikis. Alternatively, apoptosis can be induced by shedding of Fas ligand, or inhibited by release of its "death" receptor Fas/ CD95, both of which have been reported for MMP-7 [24] .
Matrix remodelling
In general, relatively little is known, in structural terms, about how cells remodel their surrounding ECM. Clearly both mechanical as well as biochemical mechanisms are involved, as shown for example by the different signalling mechanisms involved in contracting floating and restrained collagen gels [106] , or by the inability of TGF-β to induce myofibroblast differentiation unless tissues are under mechanical stress [107] . The mechanical properties of tissues such as skin are in turn largely determined by the composition and organization of the ECM, itself regulated by proteolytic and cross-linking enzymes. Matrix stiffness is a key factor in cell migration; the matrix should be stiff enough to support cell traction but not too stiff to avoid excess adhesion [108] . Cell migration is usually, but not always, accompanied by proteolytic activity, but interestingly recent observations show that the site of proteolysis is behind the leading edge of the cell, thereby allowing cells to attach to the matrix before it is degraded [109] . In this way, for example, ECM rigidity promotes increased matrix-degrading activity of invasive cells at specialized actin-rich protrusions called invadopodia or podosomes [110] . Granulation tissue formation involves the relatively rapid deposition of fibrillar collagens (mainly collagen III), fibronectin, proteoglycans and other proteins in a newly synthesized ECM. The tolloids are the group of extracellular proteases that have been most clearly linked to the process of ECM assembly [39] (figure 2). Fibrillar collagens (types I, II, III, V and XI) are synthesized in precursor form, with each molecule having both N-and Cterminal propeptide extensions [111, 112] . The propeptides help maintain solubility during synthesis of the procollagen molecule and are removed either just before or shortly after secretion into the ECM. In the case of the major fibrillagen collagens (types I, II and III), the Cpropeptides are removed by tolloid proteases, while the N-propeptides are removed by members of the ADAMTS family (types -2, -3 and -14). Following cleavage of propeptides, mature collagen molecules can then spontaneously assemble into fibrils. Proteolytic processing of procollagens V and XI is more complicated, with tolloids also being involved in the cleavage of N-propeptides and furin-like enzymes contributing to C-terminal maturation [113] . Most collagen fibrils are usually heterotypic in nature, i.e. composed of different collagen types, for examples collagen I/III/V fibrils in skin or collagen II/XI fibrils in cartilage, and it is known that such heterotypic interactions play a role in the regulation of collagen fibril diameter [111] . In addition, variations in the rates and extent of processing between different collagen types, particularly in the N-terminal regions, also contribute to diameter regulation. Collagen fibril assembly is further regulated by interactions with members of the small leucine rich proteoglycans (SLRPs, including decorin, fibromodulin, biglycan, osteoglycin), among which biglycan and osteoglycin have been shown to be cleaved by tolloid proteases [114, 115] . In the case of osteoglycin, the tolloid-dependent processing potentiates inhibition of collagen fibril assembly. Once assembled, collagen fibrils are stabilised by the formation of covalent crosslinks between neighbouring molecules, in a process catalysed by crosslinking enzymes such as lysyl oxidases and transglutaminases [116, 117] . Lysyl oxidases are themselves synthesized in a precursor form, and can be activated by tolloid protease cleavage of propeptides [118] . In addition, lysyl oxidases also act on elastin fibres as well as in bFGF and TGF-β signalling [119] . With regard to the basement membrane, tolloid proteases regulate the assembly of anchoring filaments, involved in stabilizing the dermalepidermal junction, by propeptide cleavage of the nonfibrillar procollagen VII [42] , as well as incorporation of laminin 332, by processing of the γ2 chain [41] (figure 2). Bearing in mind that tolloid proteases also catalyze the first step of TGF-β release from the matrix and that TGF-β increases the expression of most matrix components, tolloid proteases appear therefore as major hubs in the control of ECM assembly. Conversion of granulation tissue into the mature form is a process that can take several months and rarely results in the same structural and functional properties as those of the original tissue [54] . Remodelling requires the coordinated action of numerous proteases involved in ECM degradation and synthesis (essentially MMPs and ADAMTSs for the degradative part; table 1) as well as in the control of cell proliferation, differentiation, adhesion, migration and death, through the various mechanisms described above. In adults, the end result of the remodelling phase is often a scar [120] which reflects differences in the processes of repair and regeneration, where the former has evolved as a means to escape danger by rapid recovery of tissue integrity [121] . Scars are characterized by dense bundles of mostly type I collagen fibrils which appear to form during the process of wound contraction and become oriented along lines of mechanical stress [122, 123] . Wound contraction is thought to be due to the action of fibroblasts remodelling the ECM, to which they are attached through integrin receptors, either by tractional forces as they migrate through the matrix or by contraction after having differentiated into myofibroblasts [106, 124] . The process can be mimicked by cells in collagen gels, where it has been shown that contraction involves the synergistic effects of both α 2 β 1 integrin and MMPs [125] , the former mediating cell-matrix interactions and the latter facilitating cell migration through the matrix.
Conclusion
In this review, we have described the main families of proteases involved in wound healing and have given an overview of their main biological functions, all of which fall into one of the following categories: ECM synthesis and degradation; release of cryptic bioactive fragments; regulation of growth factors and cytokines; control of cell adhesion, migration, apoptosis and signalling. While the actors involved in the coordinated progression of the wound healing process are known (proteases, growth factors, other cytokines, matrix proteins and their fragments), much work remains to be done to define all the possible interactions involved. Many missing links remain between observations at the molecular and tissue levels, thereby providing major obstacles in the way of a more integrative picture of wound healing and other remodelling processes. Fortunately however, new experimental approaches are being developed that will certainly help to define the relevance of specific proteolytic events in particular tissue contexts. First, new imaging techniques are opening up new possibilities for the direct visualisation of proteolytic activity and remodelling both in vitro and in vivo. For example, visualisation of proteolytic cell migration through collagen gels has been shown to lead to re-organisation and alignment of collagen fibres [109] . Similarly, both large scale and local movements of ECM filaments, the latter driven by cell migration, have been observed by time-lapse imaging in developing embryos [126] . In addition, the use of timer reporters has allowed specific molecules to be tracked during morphogenetic changes, as for example during elastin assembly [127] . Finally, both fluorescent and radioactively labelled activity-based probes have been developed to directly visualise sites of proteolytic activity in situ, as opposed to antibody-based methods which usually do not distinguish between precursor and active forms. Such probes are easily designed for serine and cysteine proteases, for which numerous suicide substrates are known, but probes targeting metalloproteases are also under development with interesting results [128] . Also, the discovery of new protease substrates in cellbased assays has gained in efficiency with the development of quantitative proteomics and its application to proteases [1, 66] . Using iTRAQ (isobaric Tags for Relative and Absolute Quantification) and SILAC (Stable Isotope Labelling by Amino-acids in cell Culture) technologies, it is now possible, in one single experiment, to identify a large proportion of the proteins (and their fragments) found in a defined proteome and to quantify their relative abundances in several biological contexts (typically in the presence and absence of a protease). Together with knock-out mice, these new developments should contribute towards establishing the complex net-work of interactions involved in each particular remodelling event and permit the use of this knowledge to devise optimized therapeutic strategies. ■
